Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations (Unaudited)

v3.8.0.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Revenue:    
Contract research revenue $ 29,937 $ 14,969
Costs and Expenses:    
Research and development 2,192,888 2,384,218
General and administrative 1,957,798 2,117,975
Total costs and expenses 4,150,686 4,502,193
Loss from operations (4,120,749) (4,487,224)
Other income/(expense), net 10,745 (8,893)
Net loss (4,110,004) (4,496,117)
Series A convertible preferred stock accumulated dividends (147,286) (159,000)
Inducement charge from exercise of warrants (16,741,356)
Net loss attributable to common shareholders $ (4,257,290) $ (21,396,473)
Net loss available for common shareholders per share - basic and diluted $ (0.05) $ (0.25)
Weighted average common shares outstanding:    
Basic and diluted 93,542,552 84,595,597